Life Sciences Recovery And Digitalization Investments Will Improve Future Efficiency

AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Published
23 Feb 25
Updated
31 Jul 25
AnalystConsensusTarget's Fair Value
€20.56
34.6% undervalued intrinsic discount
31 Jul
€13.45
Loading
1Y
-20.0%
7D
-5.8%

Author's Valuation

€20.6

34.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 17%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 1.31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.67%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 20%

AnalystConsensusTarget has increased revenue growth from 5.8% to 6.4%.